Sources

15 Total Sources

FDA Rejects China-Invented Lung Cancer Drug After Trial Misses Survival Benefit

Left60%

Center20%

Right20%

The New York Times1h ago

F.D.A. Rejects Chinese-Invented Lung Cancer Drug Ivonescimab

Bloomberg1h ago

US FDA Rejects Summit's China-Originated Lung Cancer Drug - Bloomberg

briefs.co22h ago

FDA Rejects Summit's Ivonescimab for EGFR Lung Cancer

STAT on X: "The FDA has rejected ivonescimab, a treatment for a type of lung cancer developed by U.S. biotech Summit Therapeutics and the Chinese drugmaker Akeso. https://t.co/4BWyG1tSGF" / X

FDA rejects Summit Therapeutics and Akeso's lung cancer drug ivonescimab, saying it needs an overall survival benefit | MLQ.ai

thecatalystbrief.com8h ago

Summit Therapeutics Takes FDA Rejection For Ivonescimab In EGFR-Mutated NSCLC, Delaying U.S. Entry For PD-1xVEGF | The Catalyst Brief

FDA turns down Summit's lung cancer drug after survival result falls short · Digg

casrai.org3h ago

FDA declines ivonescimab over survival data — CASRAI

US FDA declines to approve Summit lung cancer drug after trial misses key survival goal | Reuters

zubairkhalid.com1h ago

FDA Rejects Lung Cancer Drug Ivonescimab From Summit Therapeutics | Dr. Zubair Khalid

FDA declines to approve ivonescimab for lung cancer — STAT News | UA.NEWS

US FDA declines to approve Summit lung cancer drug after trial misses key survival goal Click the link in the comments below ⬇️

Seeking Alpha1h ago

FDA declines approval of Summit's lung cancer treatment (SMMT:NASDAQ) | Seeking Alpha

Summit's PD-1xVEGF rejected by FDA in lung cancer - BioSpace

FDA Rejects Summit Therapeutics' Lung Cancer Drug Ivonescimab | KFN